novavax news
Latest from novavax
Serum Institute of India to produce 5mn Covishield doses in two months
SII has made available five to six million Covovax doses even as the demand for it is still almost zero. We will produce the same amount of Covishield doses in the next two to three months, said Adar Poonawalla
Updated on Apr 22, 2023 11:01 PM IST
Novavax 2022 Covid vaccine deliveries off to slow start, shares drop
The company has delivered 31 million doses of its vaccine against Covid-19, a small fraction of the 2 billion shots it plans to send around the world in 2022.
Updated on May 10, 2022 05:36 AM IST
Reuters |
WHO experts recommend 3rd dose of Novavax vaccine for people with health issues
The WHO's Strategic Advisory Group of Experts on Immunization, known as SAGE, issued a series of recommendations, including the use of the vaccine in persons with comorbidities, breastfeeding women, and those living with HIV.
Updated on Dec 22, 2021 04:48 AM IST
Reuters |
Novavax Covid jab gets EU medicine regulator's approval
The protein-based vaccine of the kind used around the world to protect against many childhood illnesses is the fifth coronavirus shot authorised for use in the European Union.
Published on Dec 20, 2021 08:02 PM IST
AFP |
Serum Institute to launch Covovax jab for kids in 6 months, says Adar Poonawalla
The vaccine, Poonawalla said, has shown ‘excellent data all the way down to the age group of three years.’
Published on Dec 14, 2021 02:55 PM IST
hindustantimes.com, New Delhi
Novavax COVID-19 vaccine receives its first emergency use authorization
The vaccine shot, approved in Indonesia, will be sold under the brand name of Covovax.
Updated on Nov 01, 2021 08:35 PM IST
Reuters | , New Delhi
‘Can’t launch vaccine till…’: Serum MD talks of issues between FDA and Novavax
Cyrus Poonawalla is hopeful that the issues will be resolved by October-end so that the vaccine, Covovax, can be launched in India.
Published on Aug 13, 2021 04:16 PM IST
hindustantimes.com, New Delhi
J&J and Novavax seek approval for vaccines
The J&J vaccine has been approved by several western countries and is in use in many of these, while the Novavax dose has shown some of the most promising results in clinical trials.
Updated on Aug 07, 2021 01:35 AM IST
HT Correspondent, Hindustan Times, New Delhi
'Hope to launch Covavax for adults in Oct, early 2022 for kids': Adar Poonwalla
The Serum Institute of India CEO also said that the price of the anti-Covid vaccine will be determined at the time of launch.
Published on Aug 06, 2021 06:53 PM IST
hindustantimes.com | Written by Karan Manral, New Delhi
‘Great potential’: Serum Institute begins production of 1st Covovax batch
US biotechnology company Novavax’s protein-based vaccine, NVX-CoV2373, has demonstrated 100% protection against moderate and severe disease, and 90.4% overall efficacy, in its Phase 3 trial.
Published on Jun 26, 2021 04:27 AM IST
Agencies | HT Correspondent, Hindustan Times, New Delhi
SII manufactures first batch of Covavax vaccine; Poonawalla congratulates team
The SII had earlier said that it will introduce the Covavax in the country by September.
Published on Jun 25, 2021 05:31 PM IST
hindustantimes.com | Written by Shankhyaneel Sarkar | Edited by Avik Roy, Hindustan Times, New Delhi
Serum Institute of India likely to start Covovax trials on kids by July
The trials could start by July, one of the people added on the condition of anonymity.
Published on Jun 18, 2021 05:26 AM IST
Rhythma Kaul, New Delhi
Biological E’s vaccine efficacy same as Novavax: Government panel chief
Earlier this month, the Union health ministry announced that it had finalised arrangements with the Hyderabad-based vaccine manufacturer to reserve 300 million doses
Updated on Jun 18, 2021 07:00 AM IST
Rhythma Kaul, New Delhi
SII to introduce Novavax vaccine in India by September: Report
Novavax vaccine has shown strong efficacy against the emerging variants of Covid-19 in a large trial, the biotech firm said on June 14.
Published on Jun 17, 2021 05:01 PM IST
Written by Shankhyaneel Sarkar | Edited by Poulomi Ghosh, Hindustan Times, New Delhi
Shortage of raw material holding up Covovax manufacturing
The delay in receiving raw materials such as bioreactor bags and enzymes means that SII’s launch of the Novavax vaccine, branded as Covovax in India, will not likely happen before September this year as planned originally
Updated on Jun 17, 2021 07:55 AM IST
Divya Rajagopal, New Delhi
Novavax vaccine efficacy data promising; trials in advanced stage: Centre
Novavax has a deal with Pune’s Serum Institute of India (SII) to manufacture at least a billion doses for low and middle-income countries, which includes India.
Published on Jun 15, 2021 10:06 PM IST
Written by Prashasti Singh | Edited by Avik Roy, Hindustan Times, New Delhi
Novavax vaccine 90% effective against Covid-19, says US firm
The finding is particularly encouraging for India since Novavax has a deal with Pune’s Serum Institute of India (SII) to manufacture at least a billion doses for low- and middle-income countries, which includes India.
Updated on Jun 15, 2021 12:30 AM IST
HTC and Agencies, New Delhi
Novavax combined influenza/Covid-19 vaccine shows promise in animal study
Novavax said the NanoFlu/NVX-CoV2373 vaccine elicited robust responses to both influenza A and B and protected against the SARS-CoV-2 virus.
Published on May 10, 2021 07:34 PM IST
Reuters |
Novavax starts Covid-19 vaccine trials on children
Novavax said the trials would test "the efficacy (and) safety" of the vaccine, with participants receiving either the vaccine candidate or placebo in two doses, 21 days apart.
Published on May 03, 2021 09:17 PM IST
AFP |
Novavax says supply shortages delaying production of its Covid-19 vaccine
Novavax executives had previously said full-scale vaccine production could be achieved by mid-year.
Published on Apr 13, 2021 04:21 PM IST
Reuters | | Posted by Srivatsan K C
Wall Street bets Moderna, Novavax will finally fall in 2021
Moderna Inc. and Novavax Inc. shares have run their course in the eyes of some Wall Street investors and are prime candidates for bets that they will fall this year.
Published on Apr 05, 2021 11:56 PM IST
Bloomberg |
SII begins phase 2/3 trials for Covovax, supply likely by Sept
In August 2020, US-based vaccine maker Novavax, Inc announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its Covid-19 vaccine candidate, in low and middle-income countries and India.
Updated on Mar 28, 2021 02:02 AM IST
Anonna Dutt, New Delhi
Now, SII seeks trial approval for Novavax Covid vaccine
SII is currently manufacturing Covishield, which has been developed by the University of Oxford and AstraZeneca and is one of the two coronavirus vaccines approved in the country.
Published on Jan 31, 2021 04:14 AM IST
Rhythma Kaul, New Delhi